(LABU) Direxion Daily S&P Biotech - NYSE
ETF Category: Trading--Leveraged Equity | Exchange: NYSE (USA) | Market Cap: 461m USD | Total Return: 191% in 12m
Avg Turnover: 103M
Warnings
Fakeout Volatile
Tailwinds
Rs Leader, Tailwind, Pullback Swing
The Direxion Daily S&P Biotech Bull 3X Shares (LABU) is a leveraged exchange-traded fund designed to provide 300% of the daily performance of the S&P Biotechnology Select Industry Index. To achieve this objective, the fund allocates at least 80% of its net assets to financial derivatives, including swap agreements and index-tracking securities. As a non-diversified trading vehicle, it is engineered for short-term tactical use rather than long-term investment.
The biotechnology sector is characterized by high research and development costs and a heavy reliance on intellectual property and regulatory approvals from the FDA. Unlike traditional pharmaceutical companies, many biotech firms focus on cellular and biomolecular processes to develop specialized treatments, often resulting in high stock price volatility driven by clinical trial outcomes. Investors can utilize ValueRay to further analyze the technical indicators and risk metrics associated with this leveraged fund.
- Biotech M&A activity levels drive underlying index constituent valuations
- Federal Reserve interest rate policy dictates cost of capital for pre-revenue firms
- FDA drug approval cycles and clinical trial outcomes impact sector sentiment
- Triple daily leverage amplifies volatility and creates long-term compounding decay risk
As of June 12, 2026, the stock is trading at USD 174.49 with a total of 641,151 shares traded.
Over the past week, the price has changed by -2.64%,
over one month by -8.11%,
over three months by +4.26% and
over the past year by +191.01%.
Direxion Daily S&P Biotech has no consensus analysts rating.